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Abstract
Background. The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-
NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas 
(LGGs) World Health Organization (WHO) grade II or III that present with (i) a telomerase reverse transcriptase pro-
moter mutation (pTERTmt), and/or (ii) gain of chromosome 7 combined with loss of chromosome 10, and/or (iii) 
epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2 
wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV). This paper de-
scribes the overall survival (OS) of IDH1/2wt astrocytoma WHO IV patients, and more in detail patients with tumors 
with pTERTmt only.
Methods. In this retrospective multicenter study, we compared the OS of 71 IDH1/2wt astrocytomas WHO IV pa-
tients, with radiological characteristics of LGGs, with the OS of 197 IDH1/2wt glioblastoma patients. Moreover, we 
compared the OS of 22 pTERTmt only astrocytoma patients with the OS of the IDH1/2wt glioblastoma patients.
Results. Median OS was similar for IDH1/2wt astrocytoma WHO IV patients (23.8 mo) and IDH1/2wt glioblastoma 
patients (19.2 mo) (Cox proportional hazards model: hazard ratio [HR] 1.27, 95% CI: 0.85–1.88, P = 0.242). OS was 
also similar in patients with IDH1/2wt astrocytomas WHO IV, pTERTmt only, and IDH1/2wt glioblastomas (HR 1.15, 
95% CI: 0.64–2.10, P = 0.641).
Conclusions. The presented data confirm the cIMPACT-NOW recommendation and we propose that IDH1/2wt 
astrocytomas WHO IV in the absence of other qualifying mutations should be classified as IDH1/2wt glioblastomas.
Key Points
1. IDH1/2wt astrocytomas WHO IV have a similar OS as IDH1/2wt glioblastomas.
2. pTERTmt only astrocytomas also have a similar OS as IDH1/2wt glioblastomas.
3. IDH1/2wt astrocytomas WHO IV should be classified as IDH1/2wt glioblastomas.
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The Consortium to Inform Molecular and Practical 
Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) aims 
to aid in the taxonomy of primary brain tumors in the period 
between official editions of the World Health Organization 
(WHO) classifications of brain tumors. In the third cIMPACT-
NOW report, the committee recommended to reclassify 
isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) dif-
fuse lower-grade gliomas (LGGs) of WHO grades II and 
III as diffuse astrocytic glioma, IDH1/2 wildtype, with mo-
lecular features of glioblastoma, WHO grade IV (IDH1/2wt 
astrocytomas WHO IV) if they present with (i) a telomerase 
reverse transcriptase promoter (pTERT) mutation (mt), and/
or (ii) gain of chromosome 7 combined with loss of chro-
mosome 10 (7+/10−), and/or (iii) epidermal growth factor 
receptor (EGFR) amplification (amp).1–5 Although this clas-
sification defines the diagnostic molecular criteria for 
IDH1/2wt astrocytomas WHO IV, the data on the clinical char-
acteristics and survival of these tumors are still very limited. 
Firstly, it is not clear whether the prognosis of patients pre-
senting with IDH1/2wt astrocytomas WHO IV with classical 
radiological characteristics of LGGs (ie, absence of ring-like 
contrast enhancement with central necrosis) is similar to 
the prognosis of IDH1/2wt glioblastoma patients. Secondly, 
pTERTmt IDH1/2wt astrocytomas without 7+/10− or 
EGFRamp (pTERTmt only) are now also assigned IDH1/2wt 
astrocytomas WHO IV, but it is unclear whether their prog-
nosis is indeed similar to the other IDH1/2wt astrocytomas 
WHO IV. Rare cases have been described of more benign 
types of IDH1/2wt astrocytomas harboring a pTERT mu-
tation.4,6 The main objective of this retrospective study is 
to evaluate the clinical presentation and survival outcome 
of a cohort of diffuse astrocytic glioma, IDH1/2 wildtype, 
with molecular features of glioblastoma, WHO grade IV ac-
cording to the cIMPACT-NOW criteria presenting with MRI 
characteristics of an LGG, and specifically the outcome of 
cases with pTERT mutations only.
Materials and Methods
Patient Population
In this retrospective multicenter cohort study, adult 
(≥18 y) patients with a newly diagnosed predominantly 
supratentorial IDH1/2wt LGG (WHO grade II or III) were 
identified from the Erasmus Medical Center Cancer 
Institute, the Haaglanden Medical Center, and the Leiden 
University Medical Center pathology databases as well as 
from the previously published dataset of Erasmus MC pa-
tients from Wijnenga et  al.7 Histopathological diagnoses 
were determined by local dedicated neuropathologists. 
Patients were included if (i) IDH1/2 mutation status, the 
copy number status of chromosome 7 and chromosome 
10, and the amplification status of EGFR had been assessed 
with a glioma tailored next-generation sequencing (NGS) 
panel, and (ii) MRI scans at the time of diagnostic surgery 
were available for review.8 Patients with a histological di-
agnosis of an LGG but presenting with lesions suggestive 
of glioblastoma (ring-like contrast enhancement with evi-
dence of central necrosis on the MRI at the time of histolog-
ical diagnosis) were excluded (Fig. 1A). An historical cohort 
from the Erasmus MC of IDH1/2wt glioblastoma patients 
diagnosed with the NGS panel in a routine diagnostic set-
ting between 2013 and 2019 was used to compare overall 
survival (OS).8 The design of the study was approved by the 
institutional review boards of the participating centers and 
was conducted according to national and local regulations.
Baseline Tumor Characteristics and Additional 
Molecular Analysis
For glioma targeted NGS, patient tumor material was 
cut into 5  µm formalin-fixed paraffin-embedded slices 
and selected for regions with the highest tumor cell per-
centage as defined by the local neuropathologists. DNA 
was isolated using 5% Chelex 100 resin (Bio-Rad) and pro-
teinase K digestion. NGS with a targeted neuro-oncology 
panel and single nucleotide polymorphism–based loss 
of heterozygosity analysis were performed as previously 
described.9 If pTERT status was not covered by the NGS 
panel, a SNaPshot assay was performed for the 2 hotspot 
mutations in gliomas (C228T and C250T) as previously 
described.10
Clinical Characteristics
The collected baseline clinical characteristics included 
sex, age at diagnosis, Karnofsky performance status 
(KPS) before and 3  months after surgery, date and 
Importance of the Study
The cIMPACT-NOW committee has recommended the 
classification of the new glioma subtype diffuse astro-
cytic glioma, IDH1/2 wildtype, with molecular features 
of glioblastoma, WHO grade IV. We show that these 
IDH1/2wt astrocytomas WHO IV, presenting with typ-
ical clinical, radiological, and histological characteris-
tics of diffuse lower-grade gliomas, but that have either 
a TERT promoter mutation and/or EGFR amplification 
and/or gain of chromosome 7 and loss of chromosome 
10 have a similar poor prognosis as glioblastomas. In 
the present report, all included cases had MRI scans 
that were fully consistent with a grade II or III tumor, 
and thus the histological findings do not simply repre-
sent a biopsy bias. Moreover, we identified a series of 
cases with only a TERT promoter mutation and con-
firmed their poor prognosis. Our data therefore support 
the reclassification of diffuse astrocytic glioma, IDH1/2 
wildtype, with molecular features of glioblastoma, WHO 











 user on 28 April 2020








symptom of onset, surgical procedure (biopsy or resec-
tion), histopathological diagnosis, and primary treatment 
after surgery. OS was measured from the date of the diag-
nostic MRI scan until death or was censored at the date of 
last follow-up.
Radiological Characteristics
Radiological data were taken from T2-weighted (T2w) im-
ages, T2-weighted fluid-attenuated inversion recovery 
(FLAIR) images, and T1-weighted images before and after 
intravenous contrast administration (cT1w). Baseline radi-
ological characteristics were assessed using the MRI made 
before diagnostic surgery and included tumor location 
(hemisphere, lobe[s], basal ganglia, thalamus, brainstem, 
cerebellum), growth pattern (gliomatosis cerebri, multi-
focal), and presence and pattern of contrast enhancement 
(patchy, ring-like, nodular). The MRI scans were reviewed 
by the first author (C.M.S.T.), and scans with more than 
minor contrast enhancement (patchy, nodular) were also 
reviewed by the last author (M.J.v.d.B.). The radiological 
diagnosis gliomatosis cerebri was defined as a confluent 
hyperintense FLAIR or T2w abnormality in at least 3 sepa-
rate brain lobes (Fig. 1C).
Statistical Analysis
OS was estimated using the Kaplan–Meier method and 
curves were compared using the log-rank test. Categorical 
variables were compared using Fisher’s exact test. 
Continuous numeric variables were compared using the 
Mann–Whitney U-test and the Kruskal–Wallis test. The 
Cox proportional hazards model was used for univariable 
and multivariable analysis. All factors for univariable anal-
ysis were included in the multivariable analysis based on 
known prognostic effect from previous literature.11–15 All 
P-values below 0.05 were considered to be statistically sig-




A set of 126 IDH1/2wt LGG patients as confirmed by NGS 
analysis was identified from the 3 participating centers and 
assessed for eligibility. The patients were in part identified 
from a previous study on LGGs and in part during rou-
tine diagnostics.5,7,8 Thirty-nine of these 126 patients were 
excluded: 3 patients with solely infratentorial lesions, 2 
patients with insufficient NGS data, and 34 patients with 
ring-like contrast enhancement on MRI at the time of 
  
CBA
Fig. 1 MRIs made at the time of histological diagnosis of 3 different IDH1/2wt LGG patients. (A) Ring-like contrast enhancement on cT1w im-
aging, suggestive of glioblastoma; the patient was excluded from further analysis. (B) Minor contrast enhancement on cT1w imaging, not sug-
gestive of glioblastoma; the patient was included for further analysis. (C) Typical gliomatosis cerebri on FLAIR imaging; a confluent hyperintense 












Fig. 2 A Venn diagram of the number of patients with TERT 
promoter mutations, EGFR amplification, and the signature of 
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histological diagnosis. In 29 IDH1/2wt LGG patients, minor 
enhancement was present which was fully compatible with 
a grade II or III histology and these cases were included in 
this series. The included 87 patients were reclassified into 71 
patients with molecular features of glioblastoma (IDH1/2wt 
astrocytomas WHO IV) and 16 patients without molecular 
features of glioblastoma (IDH1/2wt astrocytomas WHO II 
and III). Reclassification into IDH1/2wt astrocytomas WHO 
IV was based on the presence of a pTERT mutation in 67 
patients, EGFR amplification in 17 patients, and the com-
bined 7+/10− signature in 42 patients (Fig. 2). In 22 of 67 
pTERTmt patients the diagnosis of IDH1/2wt astrocytomas 
WHO IV was based solely on the pTERT mutation. A refer-
ence set containing 197 IDH1/2wt glioblastomas was iden-
tified from the Erasmus MC. All IDH1/2wt glioma patients 
were operated upon between October 2002 and May 2019.
The molecular features of our cohort were con-
sistent with those frequently found in astrocytic tumors 
(Fig. 3). Mutations in ATRX, BRAF, and H3F3A were only 
observed in IDH1/2wt astrocytomas WHO II and III (12.5%, 
18.8%, and 12.5%, respectively). Mutations in EGFR and 
PTEN were frequently observed in IDH1/2wt astrocytomas 
WHO IV (25.4% and 35.2%, respectively), but mutations 
in these genes were also sporadically seen in IDH1/2wt 
astrocytomas WHO II and III (6.3% and 12.5%, respectively). 
Three patients with a BRAF mutation were identified. Of 
the 2 patients with an H3F3A mutation, 1 had the H3F3A 
K27M mutation and 1 had the H3F3A G34R mutation.
Baseline Clinical and Radiological Characteristics
IDH1/2wt astrocytomas WHO IV patients had a higher 
age of onset than those with IDH1/2wt astrocytomas 
WHO II and III and IDH1/2wt glioblastomas (58 y vs 45 y 
and 55 y, respectively; P  =  0.006). IDH1/2wt astrocytoma 
WHO IV patients presented more often with epilepsy 
than the IDH1/2wt glioblastoma patients (64.8% vs 27.4%, 
P < 0.001). IDH1/2wt glioblastoma patients were operated 
upon sooner after the presenting symptom than IDH1/2wt 
astrocytomas WHO IV patients (first symptom to first sur-
gery: 1.1 mo vs 2.9 mo, P < 0.001; diagnostic scan to first 
surgery: 0.5 mo vs 1.3 mo, P < 0.001). A biopsy was per-
formed more frequently in the IDH1/2wt astrocytomas 
WHO IV compared with the IDH1/2wt astrocytomas WHO 
II and II and the IDH1/2wt glioblastomas (83.1% vs 56.2% 
and 16.8%, respectively; P  <  0.001). After the diagnostic 
surgery, IDH1/2wt glioblastomas were commonly treated 
with chemoradiation, while less than half of the IDH1/2wt 
astrocytomas WHO IV received both chemotherapy and 
radiotherapy (chemoradiation: 89.8% vs 42.3%, P < 0.001). 
Other clinical characteristics of the IDH1/2wt gliomas are 
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The MRI characteristics at the time of histological di-
agnosis of 83 IDH1/2wt LGGs are shown in Table 2. Minor 
nodular or patchy contrast enhancement was present in 
29 of the 83 IDH1/2wt LGGs (Fig. 1B). No occipital lesions 
were identified in IDH1/2wt astrocytomas WHO II and III. 
Slight infiltration into the brainstem was more frequently 
observed in IDH1/2wt astrocytomas WHO II and III com-
pared with IDH1/2wt astrocytomas WHO IV (37.5% and 
9%, respectively; P = 0.009). No other differences were ob-
served between the IDH1/2wt astrocytomas WHO IV and 
the IDH1/2wt astrocytomas WHO II and III in location distri-
bution, growth pattern (including gliomatosis cerebri), or 
presence of subtle contrast enhancement. In addition, no 
radiological differences were identified between pTERTmt 
only and other IDH1/2wt astrocytomas WHO IV. Gliomatosis 
cerebri was present in 35.8% of the IDH1/2wt astrocytomas 
WHO IV and 18.8% of the IDH1/2wt astrocytomas WHO II 
and III. The majority of the IDH1/2wt astrocytomas WHO IV 
were located in the temporal lobe, the insular region, and 
the parietal lobe. In IDH1/2wt astrocytoma WHO II and III 
patients more than half of the lesions were observed in the 
temporal lobe.
Survival Data of All IDH1/2wt Gliomas
At the time of analysis, 223 of 284 IDH1/2wt glioma pa-
tients were deceased: 53 IDH1/2wt astrocytoma WHO IV 
patients (74.6%), 165 IDH1/2wt glioblastoma patients 
(83.8%), and 5 IDH1/2wt astrocytoma WHO II and III pa-
tients (31.3%). Median follow-up of all IDH1/2wt glioma 
patients was 1.5 years (IDH1/2wt astrocytomas WHO IV: 1.4 
y, IDH1/2wt glioblastomas: 1.5 y, IDH1/2wt astrocytomas 
WHO II and III: 2.9 y; Table 1). Median OS for the IDH1/2wt 
astrocytomas WHO IV and the IDH1/2wt glioblastomas 
was similar (23.8 mo vs 19.2 mo, log-rank test: P = 0.25), 
but the median OS of the IDH1/2wt astrocytomas WHO II 
and III was significantly longer compared with the other 2 
glioma subtypes (median OS not reached, log-rank test: 
P < 0.001; Fig. 4).
Univariable analysis identified lower KPS before sur-
gery as a significant unfavorable prognostic factor for sur-
vival (KPS ≤80 vs KPS 90–100: HR 1.54, 95% CI: 1.17–2.02, 
P = 0.002; Supplementary Table 1). Other prognostic fac-
tors from univariable analysis that showed a level of signif-
icance <0.10 included sex and age of onset, in which male 
patients were associated with a worse outcome (male vs 
female: HR 1.33, 95% CI: 1.00–1.76, P = 0.05) and younger 
patients were associated with a better prognosis (<40 y 
vs 40–60 y: HR 0.62, 95% CI: 0.39–0.97; >60 y vs 40–60 y: 
HR 1.02, 95% CI: 0.77–1.36; P  =  0.07). Multivariable anal-
ysis taking into account age, sex, KPS before surgery, and 
the type of first surgery confirmed the similar survival of 
IDH1/2wt astrocytomas WHO IV and IDH1/2wt glioblast-
omas (HR 1.27, 95% CI: 0.85–1.88, P = 0.242) and the better 
survival in IDH1/2wt astrocytomas WHO II and III com-
pared with IDH1/2wt astrocytomas WHO IV (HR 0.30, 95% 
CI: 0.12–0.78, P = 0.013; Supplementary Fig. 1). Adding pri-
mary treatment after surgery to the multivariable analysis 
led to similar results, although power of the analysis was 
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The survival of the IDH1/2wt astrocytomas WHO IV, 
pTERTmt only was similar to the survival of the IDH1/2wt 
glioblastomas (median OS: 14.4 mo vs 19.2 mo, log-rank 
test: P = 0.89; Supplementary Fig. 3). At the time of anal-
ysis, 18 pTERTmt only patients (81.8%) were deceased, 
and median follow-up of the pTERTmt only patients was 
1.2  years. Univariable analysis identified both sex and 
KPS before surgery as significant prognostic factors, 
in which male patients and patients with a KPS below 
80 had a shorter OS (male vs female: HR 1.40, 95% CI: 
1.02–1.92, P = 0.04; KPS ≤80 vs KPS 90–100: HR 1.40, 95% 
CI: 1.04–1.89, P = 0.03; Supplementary Table 2). The sim-
ilar survival in IDH1/2wt astrocytomas WHO IV, pTERTmt 
only and IDH1/2wt glioblastomas remained after correc-
tion for confounding factors in multivariable analysis 
(IDH1/2wt glioblastomas vs IDH1/2wt astrocytomas WHO 
IV, pTERTmt only: HR 1.15, 95% CI: 0.64–2.10, P = 0.641; 
Supplementary Fig. 4).
In 3 pTERTmt only patients EGFR mutations were iden-
tified (A289D, A289V, and P596L). It could be argued that 
these 3 tumors should not be classified as pTERTmt only 
IDH1/2wt astrocytomas WHO IV. However, even without 
these 3 samples, survival of pTERTmt only patients was 
similar to IDH1/2wt glioblastomas (median OS: 14.4 mo vs 
19.2 mo, log-rank test: P = 0.94; Supplementary Fig. 5).
Discussion
Diffuse astrocytic glioma, IDH1/2 wildtype, with molecular 
features of glioblastoma WHO grade IV represent a new 
glioma subtype proposed by the cIMPACT-NOW committee. 
The diagnostic criteria require testing for pTERT mutation 
status, for chromosome copy alterations of chromosome 7 
and 10, and for EGFR amplification, all of which can be rou-
tinely performed. This study’s confirmation of poor survival 
in IDH1/2wt LGG patients (with clinical, radiological, and 
histological characteristics meeting the classical criteria 
for grade II or III glioma) in the presence of these molec-
ular markers supports a reclassification in the next official 
WHO classification of IDH1/2wt astrocytomas WHO IV to 
IDH1/2wt glioblastomas. Moreover, patients with IDH1/2wt 
astrocytomas with only pTERT mutations had a similar 
poor outcome.
  
Table 2 Radiological characteristics of IDH1/2wt LGGs as determined on MRI at the time of histological diagnosis* 
Characteristics IDH1/2wt Astrocytomas 
WHO IV
IDH1/2wt Astrocytomas 
WHO II and III
Pa IDH1/2wt Astrocytomas WHO IV, 
pTERTmt only
Pb
Patients, n 67 16  21  
Hemisphere, n (%)   0.636  0.933
 Right 23 (34.3) 7 (43.8)  8 (38.1)  
 Left 30 (44.8) 5 (31.3)  8 (38.1)  
 Bilateral 14 (20.9) 4 (25)  5 (23.8)  
Tumor location, 
n (%)
     
 Frontal lobe 33 (49.3) 6 (37.5) 0.421 11 (52.4) 0.391
 Parietal lobe 34 (50.7) 5 (31.3) 0.178 13 (61.9) 0.569
 Temporal lobe 50 (74.6) 10 (62.5) 0.360 18 (85.7) 1.000
 Occipital lobe 17 (25.4) 0 (0) 0.034 8 (38.1) 0.763
 Insula 39 (58.2) 6 (37.5) 0.168 15 (71.4) 0.376
 Corpus callosum 23 (34.3) 3 (18.8) 0.368 10 (47.6) 0.568
 Basal ganglia 32 (47.8) 6 (37.5) 0.580 12 (57.1) 0.567
 Thalamus 25 (37.3) 7 (43.8) 0.776 10 (47.6) 0.775
 Brainstem 6 (9) 6 (37.5) 0.009 4 (19.0) 0.223
 Cerebellar 1 (1.5) 1 (6.3) 0.350 1 (4.8) 0.420
Growth pattern, 
n (%)
     
 Gliomatosis 
cerebri
24 (35.8) 3 (18.8) 0.241 11 (52.4) 0.394
 Multifocal 6 (9.0) 1 (6.3) 1.000 1 (4.8) 0.636
Minor contrast en-
hancement, n (%)
     
 Present 21 (31.3) 8 (50) 0.146 5 (23.8) 1.000
*Only patients with available cT1w imaging and either FLAIR or T2w imaging were incorporated in this table. The indicated P-values compared a) 
IDH1/2wt astrocytomas WHO IV vs IDH1/2wt astrocytomas WHO II and III, and b) IDH1/2wt astrocytomas WHO IV, pTERTmt only vs other 
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In this cohort, we did not find a BRAF mutation in the 
IDH1/2wt astrocytomas WHO IV group and therefore also 
no BRAF mutations in the pTERTmt only group. This is im-
portant because BRAF mutations are also found in pleo-
morphic xanthoastrocytomas and these tumors may have 
pTERT mutations and a markedly improved survival com-
pared with other glioma subtypes.4,6
Of note, the OS of IDH1/2wt glioblastoma patients in our 
dataset may appear markedly longer than historical cohorts 
(19.2 mo vs 14–16 mo in large studies).13,16-18 However, the 
longer survival is largely explained by the measurement of 
OS from first diagnostic scan until death, whereas most co-
horts measure from date of randomization, which typically 
adds 2–3 months. In addition, our dataset contained a rela-
tively young population of IDH1/2wt glioblastoma patients 
and age is a well-known prognostic factor for poor survival 
in gliomas.11–15 Until recently routine NGS was only per-
formed in younger glioblastoma patients. However, after 
correction for age in the multivariable analysis the OS of 
the IDH1/2wt astrocytomas WHO IV and the IDH1/2wt glio-
blastomas remained similar.
The most important limitation of our study is its retro-
spective design. This design made it impossible to con-
trol for the treatment regimens after surgery, which may 
have impacted on survival. Due to the non-glioblastoma 
radiological and histological diagnosis, most IDH1/2wt 
astrocytomas WHO IV were treated less intensively and 
this may have adversely affected outcome. Moreover, our 
study was restricted to patients in whom IDH1/2 status 
was assessed with a glioma dedicated NGS panel. This 
was reflected in a younger IDH1/2wt glioblastoma cohort 
as mentioned earlier. Finally, we used the original clinical 
diagnosis without review, as this was the way the patients 
were initially diagnosed.
In conclusion, this study has shown similar survival of 
patients with IDH1/2wt astrocytomas WHO IV and IDH1/2wt 
glioblastomas. Furthermore, this similar survival is also 
present in IDH1/2wt astrocytoma patients with pTERTmt 
only. Our data therefore support the classification of 
IDH1/2wt astrocytomas WHO IV with the IDH1/2wt glio-
blastomas, without further distinctions. Further prospec-
tive studies should try to understand why these tumors do 
not show the classical radiological and histopathological 
characteristics of glioblastoma.
Supplementary Material





















































IDH1/2wt Astrocytoma WHO II & III 
IDH1/2wt Astrocytoma WHO IV 
IDH1/2wt Glioblastoma 
16 10 4 4 2 2 2 1 1
71 25 4 2 2 1 0 0 0
197 60 11 6 3 0 0 0 0−−
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Fig. 4 Kaplan–Meier curves of the OS of the IDH1/2wt astrocytomas WHO II and III, the IDH1/2wt astrocytomas WHO IV, and the IDH1/2wt 
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